Tear Sheet

Company Overview

HTG Molecular Diagnostics, Inc.'s mission is to empower precision medicine at the local level. The company’s proprietary HTG EdgeSeq technology automates multiplexed molecular profiling of nucleic acids in a wide variety of solid and liquid samples, even when very limited in amount. The extraction free workflow paired with detection by next-generation sequencing offers many advantages and enables meaningful applications, such as identifying biomarkers important for precision medicine, understanding the clinical relevance of these biomarkers, and, ultimately, identifying treatment options.

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG Launches HTG EdgeSeq Reveal
HTG EdgeSeq Reveal is a new software product to analyze HTG EdgeSeq Precision Immuno‑Oncology Panel data TUCSON, Ariz. , Jan. 16, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced
Toggle Summary HTG Molecular Announces Executive Transition Plan
Chief Executive Officer TJ Johnson to assume role of Executive Chairman at the end of first quarter 2019 John Lubniewski , President and Chief Operating Officer, appointed as successor TUCSON, Ariz. , Jan. 14, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc.
Toggle Summary HTG Announces Preliminary Full Year 2018 Unaudited Revenue of Approximately $21.5 Million
TUCSON, Jan. 07, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced preliminary, unaudited financial results for the full year ended December 31, 2018 .
Toggle Summary HTG Establishes a French Subsidiary to Support Expanding Growth
TUCSON, Ariz. , Dec. 18, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the formation of a French subsidiary, HTG Molecular Diagnostics France SARL (“HTG France”) in November 2018
Toggle Summary TATAA Biocenter Expands Its Next-Generation Sequencing Offerings with HTG Molecular Diagnostics' Unique HTG EdgeSeq System
GÖTEBORG, Sweden and TUSCON, Ariz., Dec. 05, 2018 (GLOBE NEWSWIRE) -- TATAA Biocenter, Europe's leading provider of genomic services, and HTG Molecular Diagnostics, Inc (HTG) (Nasdaq: HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced the

Stock Chart

SEC Filings

Filing date Description

Securities offered to employees pursuant to employee benefit plans

Report of unscheduled material events or corporate event

Report of unscheduled material events or corporate event

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities